 
Today, the U.S. Food and Drug Administration (FDA) issued a safety communication to alert patients, caregivers, and health care providers about the potential need for early device replacement of Boston Scientific Corporation (Boston Scientific) Accolade pacemaker devices, which includes the Accolade, Proponent, Essentio, and Altrua 2 Standard Life (SL) and Extended Life (EL) pacemakers, and the Visionist and Valitude cardiac resynchronization therapy pacemakers.
Boston Scientific announced a recall for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode, which has limited functionality and has been associated with the pacemaker being unable to properly regulate the heart’s rhythm and rate in some patients. A device that enters Safety Mode should be replaced. The increased risk of permanently entering Safety Mode in this subset of Accolade pacemaker devices is due to the battery underpowering the system because of a manufacturing issue.
The FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices and identify additional mitigation strategies as needed.
This safety communication provides important information about this issue including:
- Information on affected devices.
- Recommendations for patients with Accolade pacemaker devices and their caregivers.
- Recommendations for health care providers.
- Background on the issue and actions that the FDA is taking to address the issue.
- Instructions for reporting problems with Accolade pacemaker devices to the FDA.
The FDA is committed to communicating with health care providers and the public, when needed, to help ensure the health and safety of patients in support of our mission to protect and promote public health.
Questions?
If you have questions about this safety communication, contact the Division of Industry and Consumer Education (DICE).
|